Physiomics Plc (PYC)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Physiomics Plc (PYC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013628
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Physiomics plc (Physiomics) is a computational systems biology services company. It is involved in developing outsourced systems and computational systems biology models for predicting and understanding cancer drug efficacy from pre-clinical research to clinical development and finding optimal schedules. The company provides consulting services for specific pharmaceutical development projects and provides trouble-shooting services for cancer projects in exchange for product licenses and royalties. Its key services include designing optimal drug schedules, optimizing drug combinations, and single-blind validation study. The company is also involved in developing Virtual Tumour Clinical; cardiac tox prediction service; and drug combination database. Physiomics partners with small and large pharmaceutical and biotechnology companies which include Eli Lilly, Sareum, Cyclacel Pharmaceutical, Institute of Cancer Research, Cancer Research Technology, Bayer Technology Services GmbH and ValiRx. Physiomics is headquartered at Oxford, the UK.

Physiomics Plc (PYC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Physiomics Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Physiomics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Physiomics Plc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Physiomics Partners with Pharma Company 10
Physiomics Plans to Enter into Co-Development Agreement with Diatech Pharmacogenetics 11
Physiomics Enters Into Agreement With Jubilant BioSys To Offer Services In Oncology Field 12
ValiPharma Enters Into Co-Development Agreement With Physiomics 13
Physiomics Enters Into Collaboration With Pharmacometrics 14
Equity Offering 15
Physiomics Raises USD0.7 Million in Private Placement of Shares 15
Physiomics Raises USD0.4 Million in Private Placement of Shares 16
Physiomics Raises USD0.4 Million in Private Placement of Shares 17
Physiomics Raises USD0.9 Million in Private Placement 18
Physiomics Announces Private Placement Of Shares For US$6.3 Million 19
Physiomics Completes Private Placement Of US$0.97 Million 20
Physiomics Plc – Key Competitors 21
Physiomics Plc – Key Employees 22
Physiomics Plc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Oct 16, 2017: Physiomics: Final Results for the year ended 30 June 2017 24
Mar 24, 2017: Physiomics Announces Interim Results Statement for the six month period ended 31 December 2016 28
Oct 27, 2016: Physiomics: Final Results for the year ended 30 June 2016 30
Oct 25, 2016: Physiomics Announces Change of Director 32
Mar 31, 2016: Interim Results Statement for the six month period ended 31 December 2015 33
Corporate Communications 35
Apr 18, 2016: Physiomics Appoints a New Chief Executive Officer 35
Government and Public Interest 36
Jan 06, 2017: Physiomics: Confirmation of Award of Innovate UK Grant 36
Other Significant Developments 37
Oct 02, 2017: Physiomics: Company update 2017 37
May 24, 2017: Physiomics Provides Update on Two Further Extension Projects to Advance Oncology Candidate With Global Pharma Company 38
Jan 11, 2017: Physiomics: Company Update 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Physiomics Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Physiomics Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Physiomics Plc, Deals By Therapy Area, 2011 to YTD 2017 8
Physiomics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Physiomics Partners with Pharma Company 10
Physiomics Plans to Enter into Co-Development Agreement with Diatech Pharmacogenetics 11
Physiomics Enters Into Agreement With Jubilant BioSys To Offer Services In Oncology Field 12
ValiPharma Enters Into Co-Development Agreement With Physiomics 13
Physiomics Enters Into Collaboration With Pharmacometrics 14
Physiomics Raises USD0.7 Million in Private Placement of Shares 15
Physiomics Raises USD0.4 Million in Private Placement of Shares 16
Physiomics Raises USD0.4 Million in Private Placement of Shares 17
Physiomics Raises USD0.9 Million in Private Placement 18
Physiomics Announces Private Placement Of Shares For US$6.3 Million 19
Physiomics Completes Private Placement Of US$0.97 Million 20
Physiomics Plc, Key Competitors 21
Physiomics Plc, Key Employees 22

★海外企業調査レポート[Physiomics Plc (PYC)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Purdue Pharma LP:製薬・医療:M&Aディール及び事業提携情報
    Summary Purdue Pharma LP (Purdue) is a privately held, US-based pharmaceutical company which develops pharmacologic therapies for the treatment and management of pain. The company undertakes the research, development, manufacture and marketing of prescription medicines and over-the-counter (OTC) med …
  • DBV Technologies SA (DBV):製薬・医療:M&Aディール及び事業提携情報
    Summary DBV Technologies SA (DBV) is a biopharmaceutical company that develops products for the diagnosis and treatment of food and pediatric allergies. The company develops and markets non-invasive epicutaneous delivery technology and products for healthcare markets. Its viaskin technology platform …
  • Deutsche Telekom AG:企業の戦略・SWOT・財務情報
    Deutsche Telekom AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Telekom AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Mindteck (India) Limited:戦略・SWOT・企業財務分析
    Mindteck (India) Limited - Strategy, SWOT and Corporate Finance Report Summary Mindteck (India) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • The NorInchukin Bank:企業の戦略・SWOT・財務情報
    The NorInchukin Bank - Strategy, SWOT and Corporate Finance Report Summary The NorInchukin Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Berry Global Group Inc:企業の戦略・SWOT・財務分析
    Berry Global Group Inc - Strategy, SWOT and Corporate Finance Report Summary Berry Global Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Saladax Biomedical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Saladax Biomedical Inc (Saladax) is a medical equipment company that develops diagnostic tests. The company provides products such as My5-FU, MyPaclitaxel, MyImatinib and MyDocetaxel, among others. Its My5-FU measures and helps physicians to optimize a patient’s exposure to 5-fluorouracil, M …
  • MAB Discovery GmbH-製薬・医療分野:企業M&A・提携分析
    Summary MAB Discovery GmbH (MAB Discovery) is a drug discovery and development company that offers novel antibody therapeutics. The company produces monoclonal antibodies derived from rabbits and rats. It relies on natural immune response and state of the art B cell cloning techniques for the produc …
  • Lincoln Electric Holdings, Inc.:戦略・SWOT・企業財務分析
    Lincoln Electric Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Lincoln Electric Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Siemens AG (SIE):電力:M&Aディール及び事業提携情報
    Summary Siemens AG (Siemens) is a technology company that offers products and solutions for electrification, automation and digitization. The company offers products, services and solutions for power generation, transmission and distribution; oil and gas production and transportation; medical imagin …
  • Translational Drug Development LLC-製薬・医療分野:企業M&A・提携分析
    Summary Translational Drug Development LLC (TD2) is a drug development organization offers oncology treatments to cancer patients. The organization offers services which include regulatory affairs services, preclinical services, clinical services, and others. It also offers in vivo services, isogeni …
  • Beaver-Visitec International Inc:医療機器:M&Aディール及び事業提携情報
    Summary Beaver-Visitec International Inc (BVI) is a manufacturer, developer and marketer of ophthalmic and other specialty microsurgical products. The product portfolio of the company includes knives, cannulae and fluid control products, electrosurgical devices, microsurgical instruments, drapes and …
  • GP Strategies Corp (GPX):企業の財務・戦略的SWOT分析
    Summary GP Strategies Corp (GP Strategies) is a performance improvement company that offers sales and technical training, eLearning solutions, management consulting, and engineering services. The company offers solutions such as human capital management, managed learning services, off the shelf offe …
  • Cardiovascular Systems Inc (CSII):医療機器:M&Aディール及び事業提携情報
    Summary Cardiovascular Systems Inc (CSI) is a medical device company that develops and commercializes products for the treatment of peripheral and coronary vascular disease. The company's products include peripheral orbital atherectomy system, coronary orbital atherectomy system, crowns, and accesso …
  • Genocea Biosciences Inc (GNCA):企業の財務・戦略的SWOT分析
    Summary Genocea Biosciences Inc (Genocea), formerly Genocea Inc, is a cancer vaccines provider. The company discovers and develops T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. It provides Gen-009 and Gen-010 neoantigen cancer Vaccine pipeline.Genoceaatlas tec …
  • Lotus Pharmaceutical Co Ltd (1795):製薬・医療:M&Aディール及び事業提携情報
    Summary Lotus Pharmaceutical Co Ltd (Lotus Pharmaceutical), a subsidiary of Alvogen Inc is a pharmaceutical company that develops and sells pharmaceutical products. The company provides products that are used in the treatment of rheumatology, cancer, cardiology, dyslipidemia, hypertension, woman hea …
  • Companhia Energetica de Sao Paulo:発電所・企業SWOT分析
    Companhia Energetica de Sao Paulo - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Sensus Healthcare Inc (SRTS):企業の製品パイプライン分析2018
    Summary Sensus Healthcare Inc (Sensus) designs, manufactures and markets proprietary medical devices for the treatment of various types of cancers and skin diseases. The company offers superficial radiation therapy (SRT) technology based non-surgical treatment options for patients suffering from var …
  • Quorum Health Corp (QHC):企業の財務・戦略的SWOT分析
    Summary Quorum Health Corp (QHC) is a healthcare service provider that offers outpatient services. The center owns and leases hospitals and outpatient centers across the US. Its hospitals provides general hospital health-care services including general acute care, emergency room, general and special …
  • Invicta Holdings Limited:企業の戦略・SWOT・財務分析
    Invicta Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Invicta Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆